Target Angiogenesis for Lung Cancer With Multiple Tyrosine Kinase Inhibitors

Silvia Novello

SILVIA NOVELLO, University of Turin
Future improvements in drug treatment of lung cancer may be made by inhibiting more than one tyrosine kinase simultaneously. So said Silvia Novello when she presented data on a range of drugs which target angiogenesis by inhibiting more than one tyrosine kinase pathway. She talked about the evidence so far with Peter Goodwin.